Literature DB >> 11576837

mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas.

T Hagemann1, B Gunawan, M Schulz, L Füzesi, C Binder.   

Abstract

Altered expression of matrix metalloproteases (MMPs) and their inhibitors, the tissue inhibitors of matrix metalloproteases (TIMPs), has been demonstrated in various tumour tissues. mRNA expression patterns of MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, MMP-12, MMP-14 and TIMP-1, TIMP-2, TIMP-3 and TIMP-4 were evaluated by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in 30 renal cell carcinomas (RCC), as well as in the surrounding tissues. Expression of the MMPs was significantly stronger in the carcinomas than in non-malignant tissues. High levels were demonstrated particularly in clear cell RCCs (CC-RCC). Except for MMP-1, MMP expression in the papillary RCCs (P-RCC) was, for most MMPs, significantly lower. Expression of the TIMPs in malignant cells of both subtypes was weak, with the exception of TIMP-4 which was strongly expressed in the P-RCCs and downregulated in the CC-RCCs. The latter was correlated with chromosomal loss of 3p, harbouring the TIMP-4 gene locus. In conclusion, deregulated expression of the MMPs and TIMPs in RCCs differs according to histology, grade, size and cytogenetic characteristics, suggesting that MMP and TIMP expression patterns play an important role for the typical histomorphological features of RCC subtypes and their respective biological behaviour.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576837     DOI: 10.1016/s0959-8049(01)00215-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness.

Authors:  Zixi Zhang; Shaojun Zhu; Yang Yang; Xianjie Ma; Shuzhong Guo
Journal:  Tumour Biol       Date:  2015-06-04

Review 2.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

3.  Graded activation of the MEK1/MT1-MMP axis determines renal epithelial cell tumor phenotype.

Authors:  Rajeev Mahimkar; Maria Alejandra Alfonso-Jaume; Leslie M Cape; Rajvir Dahiya; David H Lovett
Journal:  Carcinogenesis       Date:  2011-09-28       Impact factor: 4.944

Review 4.  TIMPs: versatile extracellular regulators in cancer.

Authors:  Hartland W Jackson; Virginie Defamie; Paul Waterhouse; Rama Khokha
Journal:  Nat Rev Cancer       Date:  2016-12-09       Impact factor: 60.716

5.  MMP-3 expression and release by rheumatoid arthritis fibroblast-like synoviocytes induced with a bacterial ligand of integrin alpha5beta1.

Authors:  Mirjam B Zeisel; Vanessa A Druet; Dominique Wachsmann; Jean Sibilia
Journal:  Arthritis Res Ther       Date:  2004-11-24       Impact factor: 5.156

6.  Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma.

Authors:  Jinkun Han; Yajun Jing; Fubing Han; Peng Sun
Journal:  BMC Neurol       Date:  2021-11-15       Impact factor: 2.474

Review 7.  Tissue inhibitor of metalloproteinases-4. The road less traveled.

Authors:  Jorge Melendez-Zajgla; Luis Del Pozo; Gisela Ceballos; Vilma Maldonado
Journal:  Mol Cancer       Date:  2008-11-21       Impact factor: 27.401

8.  Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro.

Authors:  Tobias Engl; Jochen Rutz; Sebastian Maxeiner; Sorel Fanguen; Eva Juengel; Sebastian Koschade; Frederik Roos; Wael Khoder; Igor Tsaur; Roman A Blaheta
Journal:  Oncotarget       Date:  2018-04-10

9.  Influence of gene expression on survival of clear cell renal cell carcinoma.

Authors:  Anders Berglund; Ernest K Amankwah; Young-Chul Kim; Philippe E Spiess; Wade J Sexton; Brandon Manley; Hyun Y Park; Liang Wang; Jad Chahoud; Ratna Chakrabarti; Chang D Yeo; Hung N Luu; Giuliano D Pietro; Alexander Parker; Jong Y Park
Journal:  Cancer Med       Date:  2020-09-28       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.